Strategic partnerships AlivaMab Biologics has a history of collaborative deals with industry players (Teva, IGM Biosciences, Almirall) and is actively expanding its partner network, signaling opportunities for co-development, contracted discovery services, and early access to its fully integrated biologics platform.

Expanded discovery modules The company continually adds capability modules (fully human single-domain VH, multispecific antibodies, TCR mimic antibodies) offering a broad, modular platform that can be tailored to client needs, presenting upsell potential for customers seeking speed and de-risked discovery.

Mid-scale production With production capability up to mid-scale, ADS can support clients transitioning from discovery to early development, enabling a smoother handoff and offering a path to scale for emerging biotechs seeking integrated services.

Strategic hires Recent leadership addition in antibody engineering and protein sciences indicates a focus on strengthening technical execution and service quality, which can be leveraged to pitch premium, pharma-grade discovery and optimization solutions.

Market positioning Revenue in the low tens of millions and a network of high-profile partners position AlivaMab as an attractive collaborator for mid-sized biotechs seeking validated, de-risked discovery platforms, enabling cross-sell of modules, tools, and development services.